Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748270 | 0.82 | PARP1 (0.45) | RIPK1PARP1 | |
| SCHEMBL2986290 | 0.80 | MAPK1 (0.50) | RIPK1ABHD6 | |
| SCHEMBL20565680 | 0.78 | RIPK1 (0.51) | RIPK1 | |
| SCHEMBL20564853 | 0.77 | RIPK1 (0.67) | RIPK1PARP1CREBBP | |
| SCHEMBL3283061 | 0.77 | PDE4B (0.43) | NOTUMCREBBPPDE4BRAB9A | |
| SCHEMBL28466622 | 0.77 | AHR (0.41) | RIPK1NOTUMABHD6AHRRAB9A | |
| SCHEMBL29501124 | 0.75 | RIPK1 (0.54) | RIPK1NOTUMAHR | |
| SCHEMBL17957763 | 0.75 | RIPK1 (0.54) | RIPK1NOTUMAHR | |
| SCHEMBL1550147 | 0.74 | ABHD6 (0.60) | NOTUMABHD6RAB9ATRAP1 | |
| SCHEMBL3277637 | 0.73 | CREBBP (0.41) | CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | RIPK1 4189/4885NOTUM 1893/4885ABHD6 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.